Highlights Poseida Therapeutics, Inc.

Equities

PSTX

US73730P1084

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
2.97 ^USD	-6.01%		+1.71%	-11.61%

May. 14	Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises	MT
May. 14	Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q1 Revenue $28.1M	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises	May. 14	MT
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q1 Revenue $28.1M	May. 14	MT
Poseida Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos	May. 02	MT
Malin Corp investee signs agreement with Astellas Pharma	May. 01	AN
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences	May. 01	DJ
Poseida Therapeutics, Inc. and Xyphos Biosciences, Inc. Enter into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology	May. 01	CI
Poseida Therapeutics, Inc. Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-Allo1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma	Apr. 08	CI
Poseida Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q4 Revenue $25M	Mar. 07	MT
Poseida Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Poseida Therapeutics, Inc. Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology Annual Meeting	Dec. 10	CI
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Posts Q3 Revenue $9.4M	Nov. 09	MT
Poseida Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q2 Revenue $20M	23-08-08	MT
Poseida Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Poseida Therapeutics Secures $50 Million Strategic Investment From Astellas; Shares Gain	23-08-07	MT
Poseida Therapeutics Says US FDA Clears Investigational New Drug Application for B-cell Malignancies Treatment Candidate	23-07-05	MT
Poseida Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Poseida Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Poseida Therapeutics, Inc.

Equities

PSTX

US73730P1084

Highlights

Filters